Skip to main content
Home > Week in Review > Offerings

Chronological Index of : Financial News

 Current Issue
  • OpGen amends IPO

    OpGen Inc., Gaithersburg, Md. Business: Diagnostic, Bioinformatics, Pharmacogenetics Date announced: 2015-03-20 Type: IPO To be raised: TBD Shares: TBD Price: TBD Underwriter: Maxim Group Note: OpGen amended its IPO on …

    Published on 3/30/2015
  • Adocia S.A completes private placement

    Adocia S.A. (Euronext:ADOC; Pink:ADOCY), Lyon, France Business: Dermatology, Endocrine/Metabolic Date completed: 2015-03-27 Type: Private placement Raised: EUR32 million ($34.5 million) Shares: 621,887 Price: EUR51.40 …

    Published on 3/30/2015
  • Aeglea completes venture financing

    Aeglea Biotherapeutics Inc., Austin, Texas Business: Cancer, Endocrine/Metabolic Date completed: 2015-03-23 Type: Venture financing Raised: $44 million Investors: Lilly Ventures; Novartis Venture Funds; UT Horizon Fund;…

    Published on 3/30/2015
  • Cellectis S.A completes follow-on

    Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS), Paris, France Business: Gene/Cell therapy, Genomics Date completed: 2015-03-25 Type: Follow-on Raised: $228.3 million Shares: 5.5 million Price: $41.50 Shares after offering…

    Published on 3/30/2015
  • Cerenis Therapeutics S.A completes IPO

    Cerenis Therapeutics S.A. (Euronext:CEREN), Labege, France Business: Cardiovascular, Endocrine/Metabolic Date completed: 2015-03-26 Type: IPO Raised: EUR53.4 million ($57.7 million) Shares: 4.2 million Price: EUR12.70 …

    Published on 3/30/2015
  • Galapagos N.V completes warrant exercise

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium Business: Autoimmune, Musculoskeletal, Functional genomics Date completed: 2015-03-27 Type: Warrant exercise Raised: EUR5.8 million ($6.3 million) Shares: …

    Published on 3/30/2015
  • Gelesis completes venture financing

    Gelesis Inc., Boston, Mass. Business: Endocrine/Metabolic Date completed: 2015-03-26 Type: Venture financing Raised: $22 million Note: The offering includes the conversion of $4 million of convertible promissory notes.

    Published on 3/30/2015
  • Genetic Signatures Ltd completes IPO

    Genetic Signatures Ltd. (ASX:GSS), Darlinghurst, Australia Business: Diagnostic Date completed: 2015-03-24 Type: IPO Raised: A$7.5 million ($5.8 million) Shares: 18.8 million Price: A$0.40 Shares after offering: 72.9 …

    Published on 3/30/2015
  • HalioDx completes venture financing

    HalioDx, Marseille, France Business: Diagnostic Date completed: 2015-03-23 Type: Venture financing Raised: EUR7.5 million ($8.1 million) Investors: Sham; Sofipaca; MICare; company founders

    Published on 3/30/2015
  • Megakaryon completes venture financing

    Megakaryon Corp., Kyoto, Japan Business: Hematology Date completed: 2015-03-20 Type: Venture financing Raised: Y2.6 billion ($21.1 million) Investors: Innovation Network Corp. of Japan (INCJ); SMBC Capital; Mizuho …

    Published on 3/30/2015
  • NovaBay Pharmaceuticals Inc completes private placement of units

    NovaBay Pharmaceuticals Inc. (NYSE-M:NBY), Emeryville, Calif. Business: Infectious Date completed: 2015-03-04 Type: Private placement of units Raised: $4.9 million Units: 9.3 million Price: $0.50 (unit) Shares after …

    Published on 3/30/2015
  • Novavax Inc completes follow-on

    Novavax Inc. (NASDAQ:NVAX), Gaithersburg, Md. Business: Infectious Date completed: 2015-03-26 Type: Follow-on Raised: $175 million Shares: 24.1 million Price: $7.25 Shares after offering: 264.2 million Underwriters: …

    Published on 3/30/2015
  • OBI Pharma Inc completes IPO

    OBI Pharma Inc. (GreTai:4174), Taipei, Taiwan Business: Cancer, Infectious, Musculoskeletal Date completed: 2015-03-23 Type: IPO Raised: NT$6.2 billion ($197.2 million) Shares: 20 million Price: NT$310 Shares after …

    Published on 3/30/2015
  • Orphan Synergy Europe-Pharma S.A completes IPO

    Orphan Synergy Europe-Pharma S.A. (Euronext:OSE), Paris, France Business: Cancer, Pulmonary Date completed: 2015-03-25 Type: IPO Raised: EUR21.1 million ($22.8 million) Shares: 2 million Price: EUR10.80 Shares after …

    Published on 3/30/2015
  • Semma Therapeutics completes venture financing

    Semma Therapeutics Inc., Cambridge, Mass. Business: Endocrine/Metabolic, Gene/Cell therapy Date completed: 2015-03-24 Type: Venture financing Raised: $44 million Investors: MPM Capital; Fidelity Biosciences; Arch …

    Published on 3/30/2015
  • SteadyMed Ltd completes IPO

    SteadyMed Ltd. (NASDAQ:STDY), Rehovot, Israel Business: Drug delivery Date completed: 2015-03-25 Type: IPO Raised: $40 million Shares: 4.7 million Price: $8.50 Shares after offering: 12.7 million Underwriters: Wells …

    Published on 3/30/2015
  • Teva Pharmaceutical Industries Ltd completes private placement of senior notes

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Autoimmune, Neurology, Biosimilars Date completed: 2015-03-24 Type: Private placement of senior notes Raised: EUR2 billion ($2.2 billion) …

    Published on 3/30/2015
  • Tyme Inc completes private placement

    Tyme Inc. (OTCQB:TYMI), New York, N.Y. Business: Cancer Date completed: 2015-03-05 Type: Private placement Raised: $6.8 million Shares: 2.7 million Price: $2.50 Shares after offering: 86 million Investor: GEM Global …

    Published on 3/30/2015
  • ZS Pharma Inc completes follow-on

    ZS Pharma Inc. (NASDAQ:ZSPH), Coppell, Texas Business: Renal, Cardiovascular, Hepatic Date completed: 2015-03-25 Type: Follow-on Raised: $185.7 million Shares: 4 million Price: $46.25 Shares after offering: 24.9 million…

    Published on 3/30/2015
  • Esperion Therapeutics Inc financial update

    Esperion Therapeutics Inc. (NASDAQ:ESPR), Plymouth, Mich. Business: Endocrine/Metabolic, Cardiovascular Date announced: 2015-03-24 Note: Esperion raised $26.3 million through the sale of 262,500 shares at $100 to cover …

    Published on 3/30/2015
  • Flagship Ventures financial update

    Flagship Ventures, Cambridge, Mass. Business: Finance Date announced: 2015-03-26 Note: Flagship Ventures closed its oversubscribed Flagship Ventures Fund V at $537 million, exceeding its original target of $300 million.…

    Published on 3/30/2015
  • Joint Polish Investment Fund Management financial update

    Joint Polish Investment Fund Management, Warsaw, Poland Business: Finance Date announced: 2015-03-23 Note: Joint Polish Investment Fund Management raised $42 million in the first close of its Joint Polish Investment …

    Published on 3/30/2015
  • Retrophin Inc financial update

    Retrophin Inc. (NASDAQ:RTRX), New York, N.Y. Business: Renal, Musculoskeletal, Pulmonary Date announced: 2015-03-24 Note: Retrophin raised $19.5 million through the sale of 1 million shares at $19 to cover the …

    Published on 3/30/2015
  • Rigontec financial update

    Rigontec GmbH, Bonn, Germany Business: Cancer, Infectious Date announced: 2015-03-24 Note: Rigontec raised EUR4.8 million ($5.2 million) in a second close of a series A round, bringing the total raised in the round to …

    Published on 3/30/2015
  • Blueprint Medicines proposes IPO

    Blueprint Medicines, Cambridge, Mass. Business: Cancer Date announced: 2015-03-23 Type: IPO To be raised: Up to $100 million Shares: TBD Price: TBD Underwriters: Goldman Sachs; Cowen; JMP Securities; Wedbush Note: …

    Published on 3/30/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993